RetiSpec, Topcon Healthcare Collaborate to Bring Eye-Based AI Diagnostic Tool to the Market

Topcon Healthcare Inc. a leading provider of medical devices and software solutions has invested in RetiSpec, an innovator in AI-powered eye diagnostics for brain health. The two companies are collaborating to bring RetiSpec technology to market which aims to bring neurology and eye care closer together.
 
This collaboration will accelerate the commercialization and scale of RetiSpec’s first brain health indication for Alzheimer’s disease. It will also help in the development of additional AI-powered diagnostic solutions from the eye for early detection and monitoring of neurodegenerative diseases and side effects of the new therapies for Alzheimer’s disease.
 
RetiSpec’s eye diagnostic AI is currently only available for research and aims to help healthcare providers predict amyloid burden. This test will be integrated with Topcon Harmony, a device-inclusive and cloud-based clinical data management platform, to enable early detection of Alzheimer’s disease and facilitate timely access to care.
 
“The launch of new disease modifying therapies for Alzheimer’s disease has created a need for an affordable, accessible diagnostic solution. Dementia specialists carry overwhelming caseloads, so we urgently need better screening tools to triage to specialists early when new treatments are most efficacious at changing disease course,” commented RetiSpec CEO, Eliav Shaked. “Delivering RetiSpec’s AI-solution via the Harmony platform will help meet this need at scale, which could aid in timely medical management and more equitable access to treatment.”
 
“We are committed to accelerating innovation that enables scalable, affordable Healthcare from the Eye,” said President and CEO of Topcon Healthcare Inc. Ali Tafreshi. “RetiSpec embodies this mission by developing solutions for early detection of neurological diseases at the point of care. We are excited to empower them in the fight against Alzheimer’s disease.”